India's noodle row and spill-over effects for pharma
This article was originally published in Scrip
Executive Summary
Nestle's run-in with Indian regulators over its popular noodle brand, Maggi, being "unsafe" and hazardous" for human consumption may just have put the spotlight on the fast-growing nutraceuticals segment quite like the heightened focus on site compliance in the aftermath of "Ranbaxygate" some years ago.
You may also be interested in...
Star Power: How Celebrity Endorsement Is Shaping Pharma In India
Pharma in India draws on celebrity endorsement to spotlight specific disease conditions, with social media adding new dimensions to these efforts. But do these campaigns, now facing increasing disclosure scrutiny more widely, deliver a return on investment?
Star Power: How Celebrity Endorsement Is Shaping In India Pharma
Pharma in India draws on celebrity endorsement to spotlight specific disease conditions, with social media adding new dimensions to these efforts. But do these campaigns, now facing increasing disclosure scrutiny more widely, deliver a return on investment?
Pre-work Rigor, 'Clean' Documentation Are Key As US FDA Unlocks Remote Inspection Tools
A senior Parexel executive and ex-FDA pharmaceutical quality assessor emphasizes at a conclave why “first impressions matter now more than ever” as the agency deploys complex alternate inspections tools which the pandemic provided, and that companies need to ensure that they get things right the first time.